Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;37(6):1214-1218.
doi: 10.1038/s41433-022-02091-6. Epub 2022 May 19.

Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy

Lisa Toto  1 , Maria Ludovica Ruggeri  1 , Federica Evangelista  1 , Pasquale Viggiano  2 , Rossella D'Aloisio  3 , Chiara De Nicola  1 , Gennaro Falconio  1 , Marta Di Nicola  4 , Annamaria Porreca  4 , Rodolfo Mastropasqua  5
Affiliations

Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy

Lisa Toto et al. Eye (Lond). 2023 Apr.

Abstract

Background: To investigate choroidal vascularity index (CVI) changes after oral eplerenone treatment in chronic central serous chorioretinopathy (cCSC) using the Spectral-domain (SD)-Optical Coherence Tomography (OCT) with enhanced depth imaging (EDI) mode.

Methods: Thirty-six eyes of 18 patients suffering from cCSC with monolateral foveal subretinal fluid (FSRF) successfully treated with oral eplerenone treatment and 18 age-matched healthy subjects were enroled in this retrospective study. EDI-OCT images obtained using Heidelberg Spectralis OCT device in patients with cCSC and FSRF (group 1); fellow eye (group 2) or healthy patients (healthy) were exported and then imported into image analysis ImageJ software for subsequent quantitative analysis. The main outcome measures were luminal area (LA) and CVI.

Results: A higher value of CVI was detected in group 1 compared to healthy eyes (p = 0.006). LA and CVI significantly reduced during follow up in group 1 and group 2. LA at 120 days was significantly lower compared to all previous time points both in group 1 and group 2 (p < 0.001). Median and [1st -3rd quartile] CVI values were 0.8 [0.7; 1.1] at baseline, 0.8 [0.7; 0.9] at 30 days; 0.7 [0.6; 0.9] at 60 and 90 days and 0.6 [0.5; 0.8] at 120 days in group 1 (p = 0.007) and 0.7 [0.6; 0.9] at baseline, 0.7 [0.7; 0.8] at 30 days; 0.7 [0.6; 0.7] at 60 and 90 days and 0.6 [0.6; 0.7] at 120 days in group 2 (p = 0.018).

Conclusions: Choroidal vascularity index reduced in cCSC patients after oral eplerenone treatment during follow up both in eyes with SRF and fellow eyes thus demonstrating the effectiveness of mineral corticoid receptor antagonists in recovering choroidal morphology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Boxplot.
Boxplot and adjust p values for multiple pairwise comparing.
Fig. 2
Fig. 2. OCT imaging.
Representation of choroidal vascularity index (CVI) of a CSC eye with subfoveal subretinal fluid during follow up.
See this image and copyright information in PMC

References

    1. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burkel JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmol. 2008;115:169–73. doi: 10.1016/j.ophtha.2007.02.032. - DOI - PubMed
    1. Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY. Central serous chorioretinopathy: what we have learnt so far. Acta Ophtalmol. 2016;94:321–5. doi: 10.1111/aos.12779. - DOI - PubMed
    1. Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016;5:2. doi: 10.1167/tvst.5.2.2. - DOI - PMC - PubMed
    1. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye(Lond) 2019;33:14–33. - PMC - PubMed
    1. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672–9. doi: 10.1172/JCI61427. - DOI - PMC - PubMed

MeSH terms